Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Quest Diagnostics (NY: DGX ) 154.32 +0.37 (+0.24%) Streaming Delayed Price Updated: 10:27 AM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Quest Diagnostics < Previous 1 2 3 4 5 6 7 8 9 10 Next > What Analysts Are Saying About Quest Diagnostics Stock August 27, 2024 Via Benzinga Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain August 26, 2024 Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... Via Benzinga 8 Health Care Stocks With Whale Alerts In Today's Session August 01, 2024 Via Benzinga LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector August 01, 2024 LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... Via Benzinga Uncovering Dividend Opportunities with NYSE:DGX. July 25, 2024 Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. Via Chartmill 5 Analysts Assess Quest Diagnostics: What You Need To Know July 24, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics July 05, 2024 Via Benzinga How Is The Market Feeling About Quest Diagnostics? June 27, 2024 Via Benzinga Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says July 23, 2024 Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue... Via Benzinga Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday? July 23, 2024 Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc. Via Benzinga DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024 July 23, 2024 DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Peering Into Quest Diagnostics's Recent Short Interest June 10, 2024 Via Benzinga Analyst Scoreboard: 7 Ratings For Quest Diagnostics May 30, 2024 Via Benzinga How Is The Market Feeling About Quest Diagnostics? May 24, 2024 Via Benzinga US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist July 23, 2024 The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tuesday. The apprehensions reflect uncertainties regarding geopolitics,... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy July 18, 2024 From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology Via GlobeNewswire Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week April 29, 2024 With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. Via Benzinga Topics Stocks Exposures US Equities Peering Into Quest Diagnostics's Recent Short Interest April 24, 2024 Via Benzinga The Analyst Landscape: 5 Takes On Quest Diagnostics April 24, 2024 Via Benzinga Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally July 21, 2024 The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. Via Benzinga EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy July 18, 2024 Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... Via Benzinga S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday July 05, 2024 Via Benzinga Topics Stocks Exposures US Equities Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests June 18, 2024 Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including Via MarketBeat Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High May 15, 2024 Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered samples out of 5.5 million in 2023. The rise in synthetic urine use and... Via Benzinga Topics Cannabis Exposures Cannabis Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX April 30, 2024 Via AB Newswire Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth April 25, 2024 Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. Via Talk Markets Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic April 23, 2024 Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth. Via Benzinga DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024 April 23, 2024 DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. Via InvestorPlace US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory' April 22, 2024 Wall Street appears to be shrugging off rate worries as major stock index futures were moderately higher in early pre-market trading on Monday in the hopes of getting some respite from Big Tech... Via Benzinga Earnings Scheduled For April 23, 2024 April 23, 2024 Companies Reporting Before The Bell • RTX (NYSE:RTX) is expected to report quarterly earnings at $1.23 per share on revenue of $18.41 billion. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
